EU/3/18/1998

About

On 21 March 2018, orphan designation (EU/3/18/1998) was granted by the European Commission to Blue-Reg Europe, France, for patidegib for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome).

The sponsorship was transferred to new Pharma Gateway AB, Sweden in April 2020.

Key facts

Active substance
Patidegib
Disease / condition
Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)
Date of first decision
21/03/2018
Outcome
Positive
EU designation number
EU/3/18/1998

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Pharma Gateway AB
Johanneslundsvagen 2
Hammarby
194 61 Upplands Vaesby
Stockholms Lan
Sweden
Tel: +44 7739857736
E-mail: info@pharmagateway.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating